Anika Therapeutics (ANIK) Other Non-Current Assets (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Other Non-Current Assets of $3.0 million for Q2 2026, down 45.53% year-over-year from $5.6 million in Q2 2025, and down 29.75% quarter-over-quarter from $4.3 million in Q1 2026.
Anika Therapeutics (ANIK) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Other Non-Current Assets for 17 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 45.53% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at $3.0 million (down 45.53% YoY), while the FY2025 annual figure was $4.0 million, down 28.68% from the prior year.
- Other Non-Current Assets slipped to $3.0 million in Q2 2026 per ANIK's latest filing, from $4.3 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $36.3 million in Q4 2023 and bottomed at $3.0 million in Q2 2026.
- Historically, Other Non-Current Assets has averaged $14.0 million across 5 years, with a median of $17.4 million in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 110.84% — and 2024, when it slumped 84.42%.
- Anika Therapeutics' Other Non-Current Assets stood at $17.2 million in 2022, then surged by 110.84% to $36.3 million in 2023, then plunged by 84.42% to $5.7 million in 2024, then decreased by 28.68% to $4.0 million in 2025, then retreated by 25.06% to $3.0 million in 2026.
- Business Quant data shows ANIK's Other Non-Current Assets at $3.0 million in Q2 2026, $4.3 million in Q1 2026, and $4.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.02 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 4.03 Mn |
| Sep 30, 2025 | 5.51 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 5.73 Mn |
| Dec 31, 2024 | 5.66 Mn |
| Sep 30, 2024 | 11.31 Mn |
| Jun 30, 2024 | 19.52 Mn |
| Mar 31, 2024 | 17.57 Mn |
| Dec 31, 2023 | 36.31 Mn |
| Sep 30, 2023 | 18.95 Mn |
| Jun 30, 2023 | 19.39 Mn |
| Mar 31, 2023 | 18.13 Mn |
| Dec 31, 2022 | 17.22 Mn |
| Sep 30, 2022 | 18.34 Mn |
| Jun 30, 2022 | 20.91 Mn |
| Mar 31, 2022 | 20.39 Mn |
| Dec 31, 2021 | 20.29 Mn |
| Sep 30, 2021 | 23.67 Mn |